TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.~* Measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1, or 2~* Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug~Exclusion Criteria:~* Prior development of disease progression during high-dose dexamethasone containing therapy~* Pregnant or lactating females~* The development of a desquamating rash while taking thalidomide~* Use of any standard/experimental anti-myeloma therapy within 28 days of randomization or use of any experimental non-drug therapy within 56 days of initiation of drug treatment~* Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm3~* Laboratory abnormalities: Platelet count \< 75,000/mm3~* Laboratory abnormalities: Serum creatinine \> 2.5 mg/dL~* Laboratory abnormalities: Serum Serum glutamic oxaloacetic transaminase (SGOT)/Aspartate aminotransferase (AST) or Serum glutamic pyruvic transaminase (SGPT)/Alanine aminotransferase (ALT) \> 3.0 x upper limit of normal~* Laboratory abnormalities: Serum total bilirubin \> 2.0 mg/dL~* Prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for ≥ 3 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CC-5013 plus dexamethasone (Type: EXPERIMENTAL): Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
- Dexamethasone plus placebo (Type: EXPERIMENTAL): Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* body mass index (BMI) e30 kg/m2 in patients with or without comorbidities, or BMI \>27 kg/m2 in patients with treated or untreated hypertension and/or treated or untreated dyslipidemia.~* stable body weight (variation \<5 kg within 3 months prior to screening visit);~Exclusion Criteria:~* History of very low-calorie diet within 6 months prior to screening visit; or history of surgical procedures for body weight loss (eg, stomach stapling, bypass);~* Presence of any clinically significant psychiatric , neurological or endocrine disease~* Presence of treated or untreated type 1 or type 2 diabetes);~* SBP \>165 mmHg and/or DBP \>105 mmHg on 2 consecutive visits from the screening to the inclusion visit;~* History of myocardial infarction or unstable angina pectoris within 6 months prior to screening visit; and history of stroke within 6 months prior to screening visit;~* Administration of anti-obesity drugs or other drugs for body weight reduction within 3 months prior to screening visit;~The investigator will evaluate whether there are other reasons why a patient may not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers aged 18 to 65 years inclusive~* Body mass index (BMI) between 18 and 30 kg/m2 inclusive.~* Have no contraindications from the following: a detailed medical and surgical history, and a complete physical examination~* Able to participate, and willing to give written informed consent and to comply with the study restrictions~Exclusion Criteria:~* History of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, mental, cardiac, vascular, endocrinological, hematological or allergic disease, metabolic disorder, cancer or cirrhosis.~* History of alcohol and/or drug abuse or addiction within the last 2 years prior to Day 1 of the study.~* Consumption of nicotine and/or tobacco containing products within the last 3 months prior to Day 1 of the study.~* Infection with human immunodeficiency virus, hepatitis B and/or hepatitis C~* Any condition or disease detected during the medical interview / physical examination that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the Investigator.~* Positive drug screen or alcohol test at screening or prior to enrollment.~* Coffee or tea consumption \> 10 cups per day or methylxanthine containing drinks \>1.5 liter/day or more than 250 g/day of chocolate.~* Alcohol consumption averaging \> 3 drinks daily

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- Treatment B (Type: EXPERIMENTAL): None
- Treatment C (Type: PLACEBO_COMPARATOR): None
- Treatment D (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA~* At least one BCC tumor (greater than 4 mm in diameter) at any skin location, to be biopsied and surgically removed.~* Had at least one liver function test \[eg, aspartate aminotransferase (AST), alanine aminotransferase (ALT)\] with normal results in the last year.~* Consent to research use of their BCC tissue.~* Cohort A or B: Willing to take itraconazole during the 2 to 3 weeks between biopsy and surgical removal of BCC~EXCLUSION CRITERIA~* History or current hepatitis or other liver disease.~* Currently taking systemic medications that would affect BCC tumors (oral retinoids) or metabolism of itraconazole (anti-convulsants, corticosteroids)~* History or current evidence of malabsorption or liver disease within the one year prior to enrollment.~* History or current evidence of hyperthyroidism increasing metabolism of itraconazole~* Unable to attend to 2nd study visit at Stanford for Mohs surgical excision~* Current immunosuppression disease (cancer, autoimmune disease)~* Receiving immunosuppressive drugs~* Pregnant~* Lactating~* Any female actively trying to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A - Itraconazole 400 mg (Type: EXPERIMENTAL): Oral itraconazole 400 mg as 200 mg twice daily, for 1 month, stratified by prior vismodegib history
- Cohort B - Itraconazole 200 mg (Type: EXPERIMENTAL): Oral itraconazole 200 mg as 100 mg twice daily, for up to 3 months
- Untreated Control (Type: NO_INTERVENTION): Patients otherwise eligible but unwilling to take itraconazole were enrolled onto the control arm of the study and received no treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with high-risk hematologic malignancies with anticipated poor prognosis with non transplant therapy, including those in remission or with induction failure and after treated or untreated relapse. Diagnoses to be included a) Acute myeloid leukemia; b) Acute lymphocytic leukemia; c) Chronic myeloid leukemia; d) Chronic lymphocytic leukemia; e) Myelodysplastic syndrome; f) Myeloproliferative syndromes; g) Non-Hodgkins lymphoma; h) Hodgkins Lymphoma; i) Multiple myeloma.~2. Patients must have a histocompatible stem cell donor. An HLA-identical related donor or a 8/8 matched unrelated donor.~3. Age 5 to 75 years old.~4. Performance score of \>/= 70 by Karnofsky/Lansky or PS 0 to 1 (ECOG \</=1).~5. Left ventricular ejection fraction at least 40%.~6. Adequate pulmonary function with FEV1, FVC and DLCO \>/=50% of expected corrected for hemoglobin and/or volume. Children unable to perform pulmonary function tests (e.g., less than 7 years old) pulse oximetry of \>/= 92% on room air~7. Creatinine clearance (calculated creatinine clearance is permitted) should be \>40 ml/min.~8. Bilirubin \</= 2 x the upper limit of normal (except Gilbert's Syndrome). SGPT (ALT) \< 200.~9. Negative Beta HCG test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use an effective contraceptive measure while on study.~10. Patient or patient's legal representative, parent(s) or guardian able to sign informed consent.~Exclusion Criteria:~1. HIV seropositivity.~2. Uncontrolled infections.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine + Busulfan (Type: EXPERIMENTAL): Fludarabine administered by vein at dose of 40 mg/m2 in 100 ml of normal saline (NS) on Days -6 through -3.~First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, sexually active woman at risk for pregnancy seeking to use hormonal contraception for at least 1 year~* Ability to demonstrate willingness to participate and adhere to study protocol~Exclusion Criteria:~* Known or suspected pregnancy~* Lactating women~* Anticipates use of condoms or any other form of back-up contraception during the study~* History of dermal sensitivity to medicated patches (nicotine) or to bandages, surgical tape, etc.~* Has a contraindication to combined estrogen-progestin contraceptive use~* Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)~* Smoker who is 35 years old or over

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AG200-15 (Type: EXPERIMENTAL): AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of colorectal cancer~* No prior chemotherapy and scheduled to receive FOLFOX chemotherapy (oxaliplatin,leucovorin and 5-fluorouracil)~* Age ≥18 years~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2~* Laboratory index: Hemoglobin ≥ 90 g/L (No blood transfusion within 14 days), Absolute Neutrophil Count ≥ 1.5×10\^9/L, Platelet Count ≥ 75×10\^9/L, Serum Bilirubin ≤ 1.5×ULN, ALT and AST ≤ 3.0×ULN (without liver metastases), ALT and AST ≤ 5.0×ULN (with liver metastases), Serum Creatinine ≤ 1×ULN, Endogenous Creatinine Clearance\>60ml/min~* Be able to read, understand and complete the questionnaire and diary~* Be able to understand the study procedures and sign informed consent.~Exclusion Criteria:~* Treatment with any other study medicine within 4 weeks before enrollment.~* Nausea or vomiting ≤ 24 hours prior to registration~* Ongoing emesis due to obstruction of digestive tract~* Concurrent use of olanzapine, phenothiazine or amifostine~* Female with pregnancy or lactation~* Severe cognitive compromise~* Known history of CNS disease (e.g. brain metastases, seizure disorder)~* Concurrent abdominal radiotherapy~* Chronic alcoholism~* Known hypersensitivity to aprepitant, tropisetron, or dexamethasone.~* Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months.~* History of uncontrolled diabetes mellitus~* Serious or uncontroled infection~* Known active HIV, viral hepatitis or tuberculosis infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant arm (Type: EXPERIMENTAL): Aprepitant + Tropisetron
- Control arm (Type: ACTIVE_COMPARATOR): Dexamethasone+ Tropisetron

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of Cystic Fibrosis~* FEV1 at screening must be between 25 and 75 percent of normal predicted values for age, sex and height based on the Knudson equation~* Pseudomonas aeruginosa must be present in a sputum / deep cough throat swab culture or bronchoalveolar lavage within 6 months prior to screening and in the sputum/deep-throat cough swab culture at screening~Exclusion Criteria:~* History of sputum culture or deep cough throat swab culture yielding Burkholderia cenocepacia complex within 2 years prior to screening and /or sputum culture yielding Burkholderia cenocepacia at screening~* Hemoptysis more than 60mL at any time within 30 days prior to study drug administration~* History of hearing loss or chronic tinnitus deemed clinically significant~* Serum creatinine 2mg/dl or more, BUN 40mg/dl or more, or an abnormal urinalysis defined as 2+ or greater proteinuria at screening~* Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics~* Patients who are regularly receiving more than 1 class of inhaled anti-pseudomonal antibiotic~* Any use of inhaled or systemic anti-pseudomonal antibiotic within 28 days prior to study drug administration~* Use of loop diuretics within 7 days prior to study drug administration~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tobramycin Inhalation Powder (TIP) (Type: EXPERIMENTAL): Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psychological Influences on Postoperative Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient tonsillectomy or tonsils/adenoids~* ASA I, II~Exclusion Criteria:~* Developmental delay~* ASA III-IV~* Psychotropic medication~* Meds which interfere with metabolism of midazolam~* 36 weeks gestation

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None
- 4 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of previously untreated chronic lymphocytic leukemia (CLL)~  * Binet stage C and stage B are acceptable if there is rapid disease progression, symptoms of enlarged lymph nodes and organs, or severe B-symptoms~ * Binet stage A is acceptable, if there are B-symptoms~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 6 months~* No severe organ dysfunction~* No other previous or concurrent neoplasms, autoimmune hemolytic anemia, or thrombocytopenia~PRIOR CONCURRENT THERAPY:~* No prior or concurrent chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine plus Cyclophosphamide (Type: ACTIVE_COMPARATOR): None
- Fludarabine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of Long Term Evaluation Against LDL-C Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Complete a qualifying evolocumab (AMG 145) parent study protocol, including: 20101154 (NCT01375777), 20101155 (NCT01380730), 20090158 (NCT01375751), 20090159 (NCT01375764), and 20110231 (NCT01652703)~Exclusion Criteria:~* Experienced a treatment-related serious adverse event that led to investigational product (IP) discontinuation in the parent study~* Have an unstable medical condition, in the judgment of the investigator~* Known sensitivity to any of the products to be administered during dosing~* Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product \[all-IP\] period.
- Evolocumab + SOC (Type: EXPERIMENTAL): Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects, 18 and older subjects with visually significant cataracts and were to undergo phacoemulsification with implantation of an intracapsular positioned intraocular lens.~Exclusion Criteria:~* previous uveitis (\<1 year) previous anterior segment intraocular surgery hypersensitivity or allergy to NSAIDs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nepafenac 0.3% (Type: EXPERIMENTAL): nepafenac 0.3% ophthalmic solution dosed once daily
- Saline Solution (Type: PLACEBO_COMPARATOR): sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete